Evidence map›Paper›PMID 31966680›Full record

ArticleInternational journal of clinical and experimental pathology2017

ROS attenuates the antitumor effect of Raddeanin on ovarian cancer cells Skov3.

Fan Zhao, Yuxia Gao, Xiuming Chu, Junyu Chen, Liandi Huang, Jing Zhao, Jiayue Zhang, Shuhua Zhao

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fan ZhaoChina Japan Union Hospital, Jilin University Changchun 130041, China.
Yuxia GaoSchool of Nursing, Jilin University Changchun 130021, China.
Xiuming ChuThe Second Hospital, Jilin University Changchun 130041, China.
Junyu ChenThe Second Hospital, Jilin University Changchun 130041, China.
Liandi HuangThe Second Hospital, Jilin University Changchun 130041, China.
Jing ZhaoMedical Department, Yanbian University Yanji 133000, China.
Jiayue ZhangMedical Department, Yanbian University Yanji 133000, China.
Shuhua ZhaoThe Second Hospital, Jilin University Changchun 130041, China.
Second Affiliated Hospital of Jilin University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer is the fourth commonest cause of female cancer death, but no proper evidence had proved that surgery could prolong the survival time. Hence, new effective chemotherapy is necessary to improve the survival. Raddeanin A (RA), anoleanane-type triterpenoid sponin, is isolated from Anemone raddeana. Previous study had proved that RA exerted antitumor activity through inhibiting proliferation and promoting apoptosis of some kinds of cancer cell. ROS is a double-edged sword for tumors and might contribute to therapy resistant. In this study, we discuss at the first time whether ROS was involved in the antitumor effect of RA on Skov3 cells, and analysis the mechanism. The results showed that after be treated by RA, the proliferation of Skov3 was inhibited, and this effect can be enhanced by ROS inhibitor NAC. Pretreated with NAC can enhance the cell cycle block but not apoptosis induced by RA. Moreover, as a by-production of RA, ROS induced autophagy can attenuate RA's antitumor activity, and autophagy inhibitor 3-MA could recover RA's antitumor effect. These results demonstrated that ROS and autophagy could be considered as two pro-tumor factors in some conditions. The combination of RA and ROS inhibitor or autophagy inhibitor or both of them may be the novel strategies at least in ovarian cancer therapy.

Indexed as

autophagycell cycleepithelial ovarian cancerRaddeanin A (RA)ROSSkov3 cells

Identifiers

PMID31966680
PMCPMC6965409
OpenAlexW3003994937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.